This site is intended for Healthcare professionals only.

Fortis Healthcare approves demerger of diagnostics business SRL Limited

Fortis Healthcare approves demerger of diagnostics business SRL Limited

Gurgaon : The Board of Directors of Fortis Healthcare Limited (“Fortis Healthcare”/ “Company”) has, at its meeting, approved a proposal to demerge its diagnostics business, including that housed in its majority owned subsidiary SRL Limited (“SRL”) into another majority owned subsidiary, Fortis Malar Hospitals Limited (“Fortis Malar”) pursuant to a composite scheme of arrangement and amalgamation. The demerger shall be followed by SRL being merged with Fortis Malar as an integral part of the same composite scheme.

Fortis Malar operates a hospital facility in Chennai and is listed on BSE. The composite scheme will also provide for the sale of its hospital business by Fortis Malar to Fortis Healthcare by way of a slump sale for a lump sum cash consideration, and the same shall precede the merger. Upon the composite scheme becoming effective, and subject to receipt of requisite regulatory and statutory approvals, the diagnostics business of Fortis Healthcare, including that housed in SRL would be vested in Fortis Malar. The name of Fortis Malar will subsequently be changed to SRL Limited and this company is proposed to be listed on the National Stock Exchange of India Limited (the “NSE”), in addition to its current listing on the BSE.

Upon the effectiveness of the composite scheme and as consideration towards the demerger of the diagnostics business undertaking of Fortis Healthcare, Fortis Malar would issue and allot to the equity shareholders of Fortis Healthcare, as on record date, 0.98 fully paid up equity shares of Rs 10 each of Fortis Malar for every 1 equity share of Rs 10 each held by them in Fortis Healthcare. The equity shareholders of SRL (except for Fortis Malar, who will acquire shares of SRL pursuant to the demerger) will, as a consideration towards the merger of SRL into Fortis Malar, be issued and allotted 10.8 equity shares of Rs 10 each of Fortis Malar for every 1 equity share of Rs 10 each held by them in SRL as on record date. Further, Fortis Healthcare shall pay an amount of Rs 43 Cr as lump sum consideration to Fortis Malar towards acquisition of the hospital business of Fortis Malar.

Appointed date for the slump sale, demerger and merger under the composite scheme is opening of business on 1st January, 2017. The composite scheme of arrangement and amalgamation will be subject to the various statutory and regulatory approvals including those from the stock exchanges, and shareholders, and creditors of the respective entities, and the sanction of the jurisdictional High Court.

Commenting on the scheme, Mr. Malvinder Singh, Executive Chairman, Fortis Healthcare said “We believe this will unlock immense value for all the shareholders. As a result of the new synergistic groupings, both the hospitals and diagnostic businesses will benefit from greater clarity, a stronger focus and an independent growth trajectory. Equally, this will enable the accelerated pursuit of their respective business goals while empowering them to reach their fullest potential.”

Mr. Bhavdeep Singh, CEO, Fortis Healthcare Ltd, said, “Our hospitals and diagnostics businesses continue to perform equally well. However, in the longer term, they have a growth path of their own requiring distinctive strategies. The new arrangement resulting from the demerger will harness these unique capabilities and strengths, unlocking value by combining the flexibility with a focus on rapidly scaling up operations.”

Rationale for the proposed transaction

Presently, the healthcare delivery services business i.e. hospitals and the diagnostics businesses are housed in (1) Fortis Healthcare & Fortis Malar which primarily comprise of the operating and managing of the hospitals, providing diagnosis and treatment related to multiple chronic & nonchronic specialties and diagnostics business and (2) SRL, which is engaged in diagnostics business.

The hospitals and the diagnostics businesses have distinct operating models and given the macrofundamentals of the healthcare industry, each of these provide a strong growth opportunity in the foreseeable future. Both businesses have a pan-India presence and have since their inception attained a significant size and scale in their respective segments.

As both businesses approach their next phase of growth, it would be strategically apt to have them restructured under separate entities to enable them to move forward independently, with greater focus and specialization; leveraging further on their respective capabilities and their strong brand presence.

Additionally, the proposed restructuring, would lead to a simplified organization structure assisting shareholders and investors to better understand and evaluate both businesses independently as investment options and potentially lead to a higher value illumination of each of these businesses.

Source: Press Release
0 comment(s) on Fortis Healthcare approves demerger of diagnostics business SRL Limited

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted